Skip to content
Journal article

Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.

Glackin L, Leen G, Elnazir B, Greally P...(+4 more)

Irish medical journal, vol. 102, issue 1 (2009) p. 29

  • 4


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.
  • N/A


    ScienceDirect users who have downloaded this article.
Sign in to save reference


Allergic bronchopulmonary aspergillosis (ABPA) can cause a significant clinical deterioration in patients with cystic fibrosis. There is very little research in the current literature with regard to alternatives for treatment, apart from long courses of steroids. We conducted a retrospective review of all our patients with ABPA treated with the antifungal voriconazole and found there was a significant drop in IgE levels post treatment as well as a decrease in steroid dosing. The improvement in FEV was not statistically significant; however there was a very wide variation in pre-treatment levels.

Author-supplied keywords

  • Adolescent
  • Antifungal Agents
  • Antifungal Agents: therapeutic use
  • Aspergillosis, Allergic Bronchopulmonary
  • Aspergillosis, Allergic Bronchopulmonary: drug the
  • Aspergillosis, Allergic Bronchopulmonary: etiology
  • Confidence Intervals
  • Cystic Fibrosis
  • Cystic Fibrosis: complications
  • Cystic Fibrosis: physiopathology
  • Female
  • Forced Expiratory Volume
  • Humans
  • Immunoglobulin E
  • Immunoglobulin E: blood
  • Immunoglobulin E: drug effects
  • Male
  • Pyrimidines
  • Pyrimidines: therapeutic use
  • Retrospective Studies
  • Triazoles
  • Triazoles: therapeutic use

Find this document

Cite this document

Choose a citation style from the tabs below